Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 7316492, 17 pages
http://dx.doi.org/10.1155/2016/7316492
Review Article

Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad

Laboratory of Oncology, IRCCS “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy

Received 4 April 2016; Revised 8 July 2016; Accepted 20 September 2016

Academic Editor: Kum Kum Khanna

Copyright © 2016 Angelo Sparaneo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. de la Pompa, A. Wakeham, K. M. Correia et al., “Conservation of the Notch signalling pathway in mammalian neurogenesis,” Development, vol. 124, no. 6, pp. 1139–1148, 1997. View at Google Scholar · View at Scopus
  2. E. R. Andersson and U. Lendahl, “Therapeutic modulation of Notch signalling-are we there yet?” Nature Reviews Drug Discovery, vol. 13, no. 5, pp. 357–378, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Yamamoto, K. L. Schulze, and H. J. Bellen, “Introduction to notch signaling,” Methods in Molecular Biology, vol. 1187, pp. 1–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Wakabayashi, D. V. Chartoumpekis, and T. W. Kensler, “Crosstalk between Nrf2 and Notch signaling,” Free Radical Biology and Medicine, vol. 88, pp. 158–167, 2015. View at Publisher · View at Google Scholar
  5. S. Artavanis-Tsakonas, M. D. Rand, and R. J. Lake, “Notch signaling: cell fate control and signal integration in development,” Science, vol. 284, no. 5415, pp. 770–776, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Takebe, L. Miele, P. J. Harris et al., “Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update,” Nature Reviews Clinical Oncology, vol. 12, no. 8, pp. 445–464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Espinoza and L. Miele, “Notch inhibitors for cancer treatment,” Pharmacology and Therapeutics, vol. 139, no. 2, pp. 95–110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Borggrefe and F. Oswald, “The Notch signaling pathway: transcriptional regulation at Notch target genes,” Cellular and Molecular Life Sciences, vol. 66, no. 10, pp. 1631–1646, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. E. C. Bozkulak and G. Weinmaster, “Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling,” Molecular and Cellular Biology, vol. 29, no. 21, pp. 5679–5695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Sahlgren, M. V. Gustafsson, S. Jin, L. Poellinger, and U. Lendahl, “Notch signaling mediates hypoxia-induced tumor cell migration and invasion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 17, pp. 6392–6397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. V. Gustafsson, X. Zheng, T. Pereira et al., “Hypoxia requires Notch signaling to maintain the undifferentiated cell state,” Developmental Cell, vol. 9, no. 5, pp. 617–628, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Hao, P. Rizzo, C. Osipo et al., “Notch-1 activates estrogen receptor-α-dependent transcription via IKKα in breast cancer cells,” Oncogene, vol. 29, no. 2, pp. 201–213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Hayward, T. Kalmar, and A. M. Arias, “Wnt/Notch signalling and information processing during development,” Development, vol. 135, no. 3, pp. 411–424, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Andersen, H. Uosaki, L. T. Shenje, and C. Kwon, “Non-canonical Notch signaling: emerging role and mechanism,” Trends in Cell Biology, vol. 22, no. 5, pp. 257–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. T. Baker, A. Zlobin, and C. Osipo, “Notch-EGFR/HER2 bidirectional crosstalk in breast cancer,” Frontiers in Oncology, vol. 4, article 360, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Connolly, P. Manders, P. Earls, and R. J. Epstein, “Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control,” Cancer Treatment Reviews, vol. 40, no. 2, pp. 205–214, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. E. S. Knudsen, E. M. O'Reilly, J. R. Brody, and A. K. Witkiewicz, “Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine,” Gastroenterology, vol. 150, no. 1, pp. 48–63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Damaskos, T. Karatzas, I. D. Kostakis, L. Nikolidakis, A. Kostakis, and G. Kouraklis, “Nuclear receptors in pancreatic tumor cells,” Anticancer Research, vol. 34, no. 12, pp. 6897–6911, 2014. View at Google Scholar · View at Scopus
  19. F. E. Bertrand, C. W. Angus, W. J. Partis, and G. Sigounas, “Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch,” Cell Cycle, vol. 11, no. 23, pp. 4344–4351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Tan, U. Apte, A. Micsenyi et al., “Epidermal growth factor receptor: a novel target of the Wnt/β-catenin pathway in liver,” Gastroenterology, vol. 129, no. 1, pp. 285–302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Li, J. A. Burns, C. A. Cheney et al., “Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies,” Biologics, vol. 4, pp. 163–171, 2010. View at Google Scholar
  22. C. Talora, D. C. Sgroi, C. P. Crum, and G. Paolo Dotto, “Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation,” Genes and Development, vol. 16, no. 17, pp. 2252–2263, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. T. D. Allen, E. M. Rodriguez, K. D. Jones, and J. M. Bishop, “Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma,” Cancer Research, vol. 71, no. 18, pp. 6010–6018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Sriuranpong, M. W. Borges, R. K. Ravi et al., “Notch signaling induces cell cycle arrest in small cell lung cancer cells,” Cancer Research, vol. 61, no. 7, pp. 3200–3205, 2001. View at Google Scholar · View at Scopus
  25. A. Baumgart, S. Seidl, P. Vlachou et al., “ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer,” Cancer Research, vol. 70, no. 13, pp. 5368–5378, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Zheng, C. C. de la Cruz, L. C. Sayles et al., “A rare population of CD24+ITGB4+Notchhi cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal,” Cancer Cell, vol. 24, no. 1, pp. 59–74, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. Q. Zheng, H. Qin, H. Zhang et al., “Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549,” Oncology Reports, vol. 17, no. 4, pp. 847–852, 2007. View at Google Scholar · View at Scopus
  28. M.-M. Jin, Y.-Z. Ye, Z.-D. Qian, and Y.-B. Zhang, “Notch signaling molecules as prognostic biomarkers for non-small cell lung cancer,” Oncology Letters, vol. 10, no. 5, pp. 3252–3260, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Di Cristofano and P. P. Pandolfi, “The multiple roles of PTEN in tumor suppression,” Cell, vol. 100, no. 4, pp. 387–390, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Palomero, M. L. Sulis, M. Cortina et al., “Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia,” Nature Medicine, vol. 13, no. 10, pp. 1203–1210, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. W. H. Chappell, T. D. Green, J. D. Spengeman, J. A. McCubrey, S. M. Akula, and F. E. Bertrand, “Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1,” Cell Cycle, vol. 4, no. 10, pp. 1389–1395, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. T. Whelan, S. L. Forbes, and F. E. Bertrand, “CBF-1 (RBP-Jκ) binds to the PTEN promoter and regulates PTEN gene expression,” Cell Cycle, vol. 6, no. 1, pp. 80–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Licciulli, J. L. Avila, L. Hanlon et al., “Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53,” Cancer Research, vol. 73, no. 19, pp. 5974–5984, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Baumgart, P. K. Mazur, M. Anton et al., “Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model,” Oncogene, vol. 34, no. 5, pp. 578–588, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Graziani, S. Eliasz, M. A. De Marco et al., “Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway,” Cancer Research, vol. 68, no. 23, pp. 9678–9685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. W. A. Hassan, R. Yoshida, S. Kudoh, Y. Motooka, and T. Ito, “Evaluation of role of Notch3 signaling pathway in human lung cancer cells,” Journal of Cancer Research and Clinical Oncology, vol. 142, no. 5, pp. 981–993, 2016. View at Publisher · View at Google Scholar
  37. L. Zhou, S. Wu, L. Yu, X. Gong, W. Song, and Z. Cheng, “Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 35, no. 2, pp. 196–201, 2015. View at Google Scholar · View at Scopus
  38. T. Donnem, S. Andersen, K. Al-Shibli, S. Al-Saad, L.-T. Busund, and R. M. Bremnes, “Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival,” Cancer, vol. 116, no. 24, pp. 5676–5685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Yuan, H. Wu, H. Xu et al., “Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis,” Scientific Reports, vol. 5, article 10338, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. W. A. Hassan, R. Yoshida, S. Kudoh et al., “Notch1 controls cell chemoresistance in small cell lung carcinoma cells,” Thoracic Cancer, vol. 7, no. 1, pp. 123–128, 2016. View at Publisher · View at Google Scholar
  41. P. L. Wagner, N. Kitabayashi, C. Yao-Tseng, and A. Saqi, “Combined small cell lung carcinomas: genotypic and immunophenotypic analysis of the separate morphologic components,” American Journal of Clinical Pathology, vol. 131, no. 3, pp. 376–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. W. A. Hassan, R. Yoshida, S. Kudoh, K. Hasegawa, K. Niimori-Kita, and T. Ito, “Notch1 controls cell invasion and metastasis in small cell lung carcinoma cell lines,” Lung Cancer, vol. 86, no. 3, pp. 304–310, 2014. View at Publisher · View at Google Scholar
  43. H. Wael, R. Yoshida, S. Kudoh, K. Hasegawa, K. Niimori-Kita, and T. Ito, “Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma,” Lung Cancer, vol. 85, no. 2, pp. 131–140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Singh and J. Settleman, “EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer,” Oncogene, vol. 29, no. 34, pp. 4741–4751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. Z. Wang, Y. Li, D. Kong et al., “Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway,” Cancer Research, vol. 69, no. 6, pp. 2400–2407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Xie, L. Zhang, C.-S. He et al., “Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells,” Journal of Cellular Biochemistry, vol. 113, no. 5, pp. 1501–1513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. I. Espinoza and L. Miele, “Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells,” Cancer Letters, vol. 341, no. 1, pp. 41–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. X. Yuan, H. Wu, N. Han et al., “Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application,” Journal of Hematology and Oncology, vol. 5, no. 7, article 87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Schwanbeck, “The role of epigenetic mechanisms in notch signaling during development,” Journal of Cellular Physiology, vol. 230, no. 5, pp. 969–981, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. X.-Y. Ding, J. Ding, K. Wu et al., “Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth,” Oncogene, vol. 31, no. 23, pp. 2899–2906, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. A. M. Egloff and J. R. Grandis, “Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy,” Clinical Cancer Research, vol. 18, no. 19, pp. 5188–5195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Westhoff, I. N. Colalucaa, G. D'Ario et al., “Alterations of the Notch pathway in lung cancer,” Proceedings of the National Academy of Sciences of the United States, vol. 106, no. 52, pp. 22293–22298, 2009. View at Publisher · View at Google Scholar
  53. L. Ding, G. Getz, D. A. Wheeler et al., “Somatic mutations affect key pathways in lung adenocarcinoma,” Nature, vol. 455, no. 7216, pp. 1069–1075, 2008. View at Publisher · View at Google Scholar
  54. L. Meder, K. König, L. Ozretic et al., “NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas,” International Journal of Cancer, vol. 138, no. 4, pp. 927–938, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. J. George, J. S. Lim, S. J. Jang et al., “Comprehensive genomic profiles of small cell lung cancer,” Nature, vol. 524, no. 7563, pp. 47–53, 2015. View at Publisher · View at Google Scholar
  56. M. Kunnimalaiyaan and H. Chen, “Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors,” Oncologist, vol. 12, no. 5, pp. 535–542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. D. W. Ball, “Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer,” Cancer Letters, vol. 204, no. 2, pp. 159–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. C. M. Misquitta-Ali, E. Cheng, D. O'Hanlon et al., “Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer,” Molecular and Cellular Biology, vol. 31, no. 1, pp. 138–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. Y.-Y. Mo, H. Tang, and L. Miele, “Notch-associated microRNAs in cancer,” Current Drug Targets, vol. 14, no. 10, pp. 1157–1166, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. E. C. Lai, B. Tam, and G. M. Rubin, “Pervasive regulation of Drosophila Notch target genes by GY-box-, Brd-box-, and K-box-class microRNAs,” Genes & Development, vol. 19, no. 9, pp. 1067–1080, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Ji, Z. Wang, A. Geamanu, A. Goja, F. H. Sarkar, and S. V. Gupta, “Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells,” International Journal of Cancer, vol. 131, no. 11, pp. 2668–2677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Motohashi and M. Yakamoto, “Carcinogenesis and transcriptional regulation through Maf recognition elements,” Cancer Science, vol. 98, no. 2, pp. 135–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Kobayashi, M.-I. Kang, H. Okawa et al., “Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2,” Molecular and Cellular Biology, vol. 24, no. 16, pp. 7130–7139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Canning, F. J. Sorrell, and A. N. Bullock, “Structural basis of Keap1 interactions with Nrf2,” Free Radical Biology and Medicine, vol. 88, pp. 101–107, 2015. View at Publisher · View at Google Scholar
  65. P. Canning, C. D. O. Cooper, T. Krojer et al., “Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases,” Journal of Biological Chemistry, vol. 288, no. 11, pp. 7803–7814, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. K. R. Sekhar, G. Rachakonda, and M. L. Freeman, “Cysteine-based regulation of the CUL3 adaptor protein Keap1,” Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 21–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. K. I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, and M. Yamamoto, “Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model,” Molecular and Cellular Biology, vol. 26, no. 8, pp. 2887–2900, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. T. H. Rushmore, M. R. Morton, and C. B. Pickett, “The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity,” The Journal of Biological Chemistry, vol. 266, no. 18, pp. 11632–11639, 1991. View at Google Scholar · View at Scopus
  69. B. M. Hybertson and B. Gao, “Role of the Nrf2 signaling system in health and disease,” Clinical Genetics, vol. 86, no. 5, pp. 447–452, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Malhotra, E. Portales-Casamar, A. Singh et al., “Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through chip-seq profiling and network analysis,” Nucleic Acids Research, vol. 38, no. 17, pp. 5718–5734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. I. Gañán-Gómez, Y. Wei, H. Yang, M. C. Boyano-Adánez, and G. García-Manero, “Oncogenic functions of the transcription factor Nrf2,” Free Radical Biology and Medicine, vol. 65, pp. 750–764, 2013. View at Publisher · View at Google Scholar
  72. Y. Mitsuishi, K. Taguchi, Y. Kawatani et al., “Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming,” Cancer Cell, vol. 22, no. 1, pp. 66–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. K. Niture and A. K. Jaiswal, “Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance,” Free Radical Biology and Medicine, vol. 57, pp. 119–131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. S. K. Niture and A. K. Jaiswal, “Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis,” The Journal of Biological Chemistry, vol. 287, no. 13, pp. 9873–9886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Taguchi, H. Motohashi, and M. Yamamoto, “Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution,” Genes to Cells, vol. 16, no. 2, pp. 123–140, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. M. T. Landi, T. Dracheva, M. Rotunno et al., “Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival,” PLoS ONE, vol. 3, no. 2, Article ID e1651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. The Cancer Genome Atlas Research Network, “Comprehensive genomic characterization of squamous cell lung cancers,” Nature, vol. 489, no. 7417, pp. 519–525, 2012. View at Publisher · View at Google Scholar
  78. N. Rekhtman, M. C. Pietanza, M. D. Hellmann et al., “Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets,” Clinical Cancer Research, vol. 22, no. 14, pp. 3618–3629, 2016. View at Publisher · View at Google Scholar
  79. H. Satoh, T. Moriguchi, J. Takai, M. Ebina, and M. Yamamoto, “Nrf2 prevents initiation but accelerates progression through the kras signaling pathway during lung carcinogenesis,” Cancer Research, vol. 73, no. 13, pp. 4158–4168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. H. M. Leinonen, E. Kansanen, P. Pölönen, M. Heinäniemi, and A.-L. Levonen, “Dysregulation of the Keap1-Nrf2 pathway in cancer,” Biochemical Society Transactions, vol. 43, no. 4, pp. 645–649, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Huang, W. Li, Z.-Y. Su, and A.-N. T. Kong, “The complexity of the Nrf2 pathway: beyond the antioxidant response,” Journal of Nutritional Biochemistry, vol. 26, no. 12, pp. 1401–1413, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Murakami and H. Motohashi, “Roles of Nrf2 in cell proliferation and differentiation,” Free Radical Biology and Medicine B, vol. 88, pp. 168–178, 2015. View at Publisher · View at Google Scholar
  83. H. Yang, W. Wang, Y. Zhang et al., “The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer,” Clinical Lung Cancer, vol. 12, no. 3, pp. 166–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. L. M. Solis, C. Behrens, W. Dong et al., “Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features,” Clinical Cancer Research, vol. 16, no. 14, pp. 3743–3753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. D. W. Cescon, D. She, S. Sakashita et al., “NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma,” Clinical Cancer Research, vol. 21, no. 11, pp. 2499–2505, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. L. A. Muscarella, P. Parrella, V. D'Alessandro et al., “Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer,” Epigenetics, vol. 6, no. 6, pp. 710–719, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Takahashi, M. Sonobe, T. Menju et al., “Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer,” Journal of Surgical Oncology, vol. 101, no. 6, pp. 500–506, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. M. S. Degese, J. E. Mendizabal, N. A. Gandini et al., “Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data,” Lung Cancer, vol. 77, no. 1, pp. 168–175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. J.-R. Tsai, H.-M. Wang, P.-L. Liu et al., “High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients,” Cellular Oncology, vol. 35, no. 6, pp. 461–471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. J. M. Kolesar, S. C. Pritchard, K. M. Kerr, K. Kim, M. C. Nicolson, and H. McLeod, “Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue,” International Journal of Oncology, vol. 21, no. 5, pp. 1119–1124, 2002. View at Publisher · View at Google Scholar
  91. J. M. Kolesar, S. E. Dahlberg, S. Marsh et al., “The NQO12/2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer,” Oncology Reports, vol. 25, no. 6, pp. 1765–1772, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. Z. Li, Y. Zhang, T. Jin et al., “NQO1 protein expression predicts poor prognosis of non-small cell lung cancers,” BMC Cancer, vol. 15, no. 1, article 207, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. Z. Qian, T. Zhou, C. I. Gurguis et al., “Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival,” Scientific Reports, vol. 5, article 16889, 2015. View at Publisher · View at Google Scholar
  94. M. E. Abazeed, D. J. Adams, K. E. Hurov et al., “Integrative radiogenomic profiling of squamous cell lung cancer,” Cancer Research, vol. 73, no. 20, pp. 6289–6298, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Tao, S. Wang, S. J. Moghaddam et al., “Oncogenic KRAS confers chemoresistance by upregulating NRF2,” Cancer Research, vol. 74, no. 24, pp. 7430–7441, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. P. Y. Yip, “Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer,” Translational Lung Cancer Research, vol. 4, no. 2, pp. 165–176, 2015. View at Google Scholar
  97. S. Lee, M.-J. Lim, M.-H. Kim et al., “An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses,” Free Radical Biology and Medicine, vol. 53, no. 4, pp. 807–816, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. T. D. Clay, P. A. Russell, H. Do et al., “Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations,” Pathology, vol. 48, no. 1, pp. 17–24, 2016. View at Publisher · View at Google Scholar
  99. B. Lee, T. Lee, S. H. Lee, Y. L. Choi, and J. Han, “Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers,” Oncotarget, vol. 7, no. 17, pp. 23874–23884, 2016. View at Publisher · View at Google Scholar
  100. G. M. DeNicola, F. A. Karreth, T. J. Humpton et al., “Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis,” Nature, vol. 475, no. 7354, pp. 106–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Singh, V. Misra, R. K. Thimmulappa et al., “Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer,” PLoS Medicine, vol. 3, no. 10, article e420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. S. K. Niture and A. K. Jaiswal, “Prothymosin-α mediates nuclear import of the INrf2/ Cul3·Rbx1 complex to degrade nuclear Nrf2,” The Journal of Biological Chemistry, vol. 284, no. 20, pp. 13856–13868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. O.-H. Lee, A. K. Jain, V. Papusha, and A. K. Jaiswal, “An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance,” Journal of Biological Chemistry, vol. 282, no. 50, pp. 36412–36420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. Z. Sun, S. Zhang, J. Y. Chan, and D. D. Zhang, “Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2,” Molecular and Cellular Biology, vol. 27, no. 18, pp. 6334–6349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. Y. Mitsuishi, H. Motohashi, and M. Yamamoto, “The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism,” Frontiers in Oncology, vol. 2, article 200, 2012. View at Publisher · View at Google Scholar
  106. T. Shibata, T. Ohta, K. I. Tong et al., “Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13568–13573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. R. Kim, J. E. Oh, M. S. Kim et al., “Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin,” Journal of Pathology, vol. 220, no. 4, pp. 446–451, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM), “A genomics-based classification of human lung tumors,” Science Translational Medicine, vol. 5, no. 209, p. 209ra153, 2013. View at Publisher · View at Google Scholar
  109. Y. Kim, P. S. Hammerman, J. Kim et al., “Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients,” Journal of Clinical Oncology, vol. 32, no. 2, pp. 121–128, 2014. View at Publisher · View at Google Scholar
  110. Q. K. Li, A. Singh, S. Biswal, F. Askin, and E. Gabrielson, “KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma,” Journal of Human Genetics, vol. 56, no. 3, pp. 230–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. J. M. Kaufman, J. M. Amann, K. Park et al., “LKB1 loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT,” Journal of Thoracic Oncology, vol. 9, no. 6, pp. 794–804, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. L. Fernandez-Cuesta, M. Peifer, X. Lu et al., “Abstract 1531: cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets,” Cancer Research, vol. 74, no. 19, supplement, 2014. View at Publisher · View at Google Scholar
  113. Z. Li, L. Xu, N. Tang et al., “The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2,” FEBS Letters, vol. 588, no. 17, pp. 3000–3007, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. M. T. M. Van Jaarsveld, J. Helleman, A. W. M. Boersma et al., “miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells,” Oncogene, vol. 32, no. 36, pp. 4284–4293, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. B. N. Chorley, M. R. Campbell, X. Wang et al., “Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha,” Nucleic Acids Research, vol. 40, no. 15, pp. 7416–7429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. N. M. Shah, S. A. Rushworth, M. Y. Murray, K. M. Bowles, and D. J. MacEwan, “Understanding the role of NRF2-regulated miRNAs in human malignancies,” Oncotarget, vol. 4, no. 8, pp. 1130–1142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Duru, R. Gernapudi, Y. Zhang et al., “NRF2/miR-140 signaling confers radioprotection to human lung fibroblasts,” Cancer Letters, vol. 369, no. 1, pp. 184–191, 2015. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Murray-Stewart, C. L. Hanigan, P. M. Woster, L. J. Marton, and R. A. Casero Jr., “Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism,” Molecular Cancer Therapeutics, vol. 12, no. 10, pp. 2088–2099, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Guo, S. Yu, C. Zhang, and A. N. Kong, “Epigenetic regulation of Keap1-Nrf2 signaling,” Free Radical Biology & Medicine, vol. 88, part B, pp. 337–349, 2015. View at Publisher · View at Google Scholar
  120. R. Wang, J. An, F. Ji, H. Jiao, H. Sun, and D. Zhou, “Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues,” Biochemical and Biophysical Research Communications, vol. 373, no. 1, pp. 151–154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. X. Liu, C. Sun, B. Liu et al., “Genistein mediates the selective radiosensitizing effect in NSCLC A549 cells via inhibiting methylation of the keap1 gene promoter region,” Oncotarget, vol. 7, no. 19, pp. 27267–27279, 2016. View at Publisher · View at Google Scholar
  122. Z. Chen, X. Ye, N. Tang et al., “The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer,” British Journal of Pharmacology, vol. 171, no. 13, pp. 3196–3211, 2014. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Singh, C. Happel, S. K. Manna et al., “Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis,” The Journal of Clinical Investigation, vol. 123, no. 7, pp. 2921–2934, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. C. Xia, X. Bai, X. Hou et al., “Cryptotanshinone reverses cisplatin resistance of human lung carcinoma A549 cells through down-regulating Nrf2 pathway,” Cellular Physiology and Biochemistry, vol. 37, no. 2, pp. 816–824, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. X. Tang, H. Wang, L. Fan et al., “Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs,” Free Radical Biology and Medicine, vol. 50, no. 11, pp. 1599–1609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Chian, R. Thapa, Z. Chi, X. J. Wang, and X. Tang, “Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo,” Biochemical and Biophysical Research Communications, vol. 447, no. 4, pp. 602–608, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Homma, Y. Ishii, Y. Morishima et al., “Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer,” Clinical Cancer Research, vol. 15, no. 10, pp. 3423–3432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Vartanian, T. P. Ma, J. Lee et al., “Application of mass spectrometry profiling to establish brusatol as an inhibitor of global protein synthesis,” Molecular & Cellular Proteomics, vol. 15, no. 4, pp. 1220–1231, 2016. View at Publisher · View at Google Scholar
  129. K. Wang, T. Zhang, Q. Dong, E. C. Nice, C. Huang, and Y. Wei, “Redox homeostasis: the linchpin in stem cell self-renewal and differentiation,” Cell Death and Disease, vol. 4, no. 3, article e537, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. C. E. Hochmuth, B. Biteau, D. Bohmann, and H. Jasper, “Redox regulation by keap1 and Nrf2 controls intestinal stem cell proliferation in drosophila,” Cell Stem Cell, vol. 8, no. 2, pp. 188–199, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. Y.-Y. Jang and S. J. Sharkis, “A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche,” Blood, vol. 110, no. 8, pp. 3056–3063, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. J. E. Le Belle, N. M. Orozco, A. A. Paucar et al., “Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner,” Cell Stem Cell, vol. 8, no. 1, pp. 59–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. J. J. Tsai, J. A. Dudakov, K. Takahashi et al., “Nrf2 regulates haematopoietic stem cell function,” Nature Cell Biology, vol. 15, no. 3, pp. 309–316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. N. Wakabayashi, S. Shin, S. L. Slocum et al., “Regulation of Notch1 signaling by Nrf2: implications for tissue regeneration,” Science Signaling, vol. 3, no. 130, article ra52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. Y. Zong, A. Panikkar, J. Xu et al., “Notch signaling controls liver development by regulating biliary differentiation,” Development, vol. 136, no. 10, pp. 1727–1739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. N. Wakabayashi, J. J. Skoko, D. V. Chartoumpekis et al., “Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by notch signaling,” Molecular and Cellular Biology, vol. 34, no. 4, pp. 653–663, 2014. View at Publisher · View at Google Scholar · View at Scopus
  137. E. Barreiro, V. I. Peinado, J. B. Galdiz et al., “Cigarette smoke-induced oxidative stress: a role in chronic obstructive pulmonary disease skeletal muscle dysfunction,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 4, pp. 477–488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. M. K. Paul, B. Bisht, D. O. Darmawan et al., “Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent notch signaling,” Cell Stem Cell, vol. 15, no. 2, pp. 199–214, 2014. View at Publisher · View at Google Scholar · View at Scopus
  139. C. D. Peacock and D. N. Watkins, “Cancer stem cells and the ontogeny of lung cancer,” Journal of Clinical Oncology, vol. 26, no. 17, pp. 2883–2889, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. N. Wakabayashi, S. L. Slocum, J. J. Skoko, S. Shin, and T. W. Kensler, “When NRF2 talks, who's listening?” Antioxidants & Redox Signaling, vol. 13, no. 11, pp. 1649–1663, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. Q. Zhao, A. Mao, J. Yan et al., “Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells,” International Journal of Oncology, vol. 48, no. 2, pp. 765–773, 2016. View at Publisher · View at Google Scholar · View at Scopus
  142. M. S. Lawrence, P. Stojanov, C. H. Mermel et al., “Discovery and saturation analysis of cancer genes across 21 tumour types,” Nature, vol. 505, no. 7484, pp. 495–501, 2014. View at Publisher · View at Google Scholar · View at Scopus
  143. N. Takebe, D. Nguyen, and S. X. Yang, “Targeting Notch signaling pathway in cancer: clinical development advances and challenges,” Pharmacology and Therapeutics, vol. 141, no. 2, pp. 140–149, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. X. Yuan, H. Wu, H. Xu et al., “Notch signaling: an emerging therapeutic target for cancer treatment,” Cancer Letters, vol. 369, no. 1, pp. 20–27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  145. Y. Wu, C. Cain-Hom, L. Choy et al., “Therapeutic antibody targeting of individual Notch receptors,” Nature, vol. 464, no. 7291, pp. 1052–1057, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. R. Olsauskas-Kuprys, A. Zlobin, and C. Osipo, “Gamma secretase inhibitors of Notch signaling,” OncoTargets and Therapy, vol. 6, pp. 943–955, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. W. A. Messersmith, G. I. Shapiro, J. M. Cleary et al., “A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014,” Clinical Cancer Research, vol. 21, no. 1, pp. 60–67, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. W.-C. Yen, M. M. Fischer, F. Axelrod et al., “Targeting notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency,” Clinical Cancer Research, vol. 21, no. 9, pp. 2084–2095, 2015. View at Publisher · View at Google Scholar · View at Scopus
  149. M. C. Pietanza, L. A. Byers, J. D. Minna, and C. M. Rudin, “Small cell lung cancer: will recent progress lead to improved outcomes?” Clinical Cancer Research, vol. 21, no. 10, pp. 2244–2255, 2015. View at Publisher · View at Google Scholar · View at Scopus
  150. A. Ahmad, W. A. Sakr, and K. M. Rahman, “Novel targets for detection of cancer and their modulation by chemopreventive natural compounds,” Frontiers in Bioscience, vol. 4, pp. 410–425, 2012. View at Google Scholar
  151. S. N. Pinchot, R. Jaskula-Sztul, L. Ning et al., “Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method,” Cancer, vol. 117, no. 7, pp. 1386–1398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. D. Subramaniam, N. D. Nicholes, A. Dhar et al., “3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis,” Molecular Cancer Therapeutics, vol. 10, no. 11, pp. 2146–2156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  153. M. C. Jaramillo and D. D. Zhang, “The emerging role of the Nrf2-Keap1 signaling pathway in cancer,” Genes & Development, vol. 27, no. 20, pp. 2179–2191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  154. J. W. Xiu, J. D. Hayes, C. J. Henderson, and C. R. Wolf, “Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19589–19594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. S. H. Ki, I. J. Cho, D. W. Choi, and S. G. Kim, “Glucocorticoid Receptor (GR)-associated SMRT binding to C/EBPβ TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 gene repression,” Molecular and Cellular Biology, vol. 25, no. 10, pp. 4150–4165, 2005. View at Publisher · View at Google Scholar
  156. L. Yang, D. L. Palliyaguru, and T. W. Kensler, “Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane,” Seminars in Oncology, vol. 43, no. 1, pp. 146–153, 2016. View at Publisher · View at Google Scholar
  157. F. Hong, M. L. Freeman, and D. C. Liebler, “Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane,” Chemical Research in Toxicology, vol. 18, no. 12, pp. 1917–1926, 2005. View at Publisher · View at Google Scholar · View at Scopus
  158. D. Kalpana Deepa Priya, R. Gayathri, and D. Sakthisekaran, “Role of sulforaphane in the anti-initiating mechanism of lung carcinogenesis in vivo by modulating the metabolic activation and detoxification of benzo(a)pyrene,” Biomedicine and Pharmacotherapy, vol. 65, no. 1, pp. 9–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  159. G. H. Jo, G.-Y. Kim, W.-J. Kim, K. Y. Park, and Y. H. Choi, “Sulforaphane induces apoptosis in T24 human urinary bladder cancer cells through a reactive oxygen species-mediated mitochondrial pathway: the involvement of endoplasmic reticulum stress and the Nrf2 signaling pathway,” International Journal of Oncology, vol. 45, no. 4, pp. 1497–1506, 2014. View at Publisher · View at Google Scholar · View at Scopus
  160. S. H. Choi, Y. M. Kim, J. M. Lee, and S. G. Kim, “Antioxidant and mitochondrial protective effects of oxidized metabolites of oltipraz,” Expert Opinion on Drug Metabolism and Toxicology, vol. 6, no. 2, pp. 213–224, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. S. Sharma, P. Gao, and V. E. Steele, “The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model,” Carcinogenesis, vol. 27, no. 8, pp. 1721–1727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  162. A. Kode, S. Rajendrasozhan, S. Caito, S.-R. Yang, I. L. Megson, and I. Rahman, “Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 294, no. 3, pp. L478–L488, 2008. View at Publisher · View at Google Scholar · View at Scopus
  163. R. Garg, S. Gupta, and G. B. Maru, “Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action,” Carcinogenesis, vol. 29, no. 5, pp. 1022–1032, 2008. View at Publisher · View at Google Scholar · View at Scopus
  164. Y. Li, J. Zhang, D. Ma et al., “Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling,” The FEBS Journal, vol. 279, no. 12, pp. 2247–2259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  165. S. Magesh, Y. Chen, and L. Hu, “Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents,” Medicinal Research Reviews, vol. 32, no. 4, pp. 687–726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  166. L. Hu, S. Magesh, L. Chen et al., “Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 10, pp. 3039–3043, 2013. View at Publisher · View at Google Scholar · View at Scopus
  167. Z.-Y. Jiang, M.-C. Lu, L.-L. Xu et al., “Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis,” Journal of Medicinal Chemistry, vol. 57, no. 6, pp. 2736–2745, 2014. View at Publisher · View at Google Scholar · View at Scopus
  168. F. Radtke and K. Raj, “The role of Notch in tumorigenesis: oncogene or tumour suppressor,” Nature Reviews Cancer, vol. 3, no. 10, pp. 756–767, 2003. View at Publisher · View at Google Scholar · View at Scopus
  169. A. Lau, N. F. Villeneuve, Z. Sun, P. K. Wong, and D. D. Zhang, “Dual roles of Nrf2 in cancer,” Pharmacological Research, vol. 58, no. 5-6, pp. 262–270, 2008. View at Publisher · View at Google Scholar · View at Scopus